Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21481959 | 0.91 | — | — | |
| SCHEMBL20334521 | 0.87 | LGALS8 (0.33) | — | |
| SCHEMBL12292292 | 0.87 | LGALS8 (0.33) | — | |
| SCHEMBL19661469 | 0.87 | LGALS8 (0.33) | — | |
| SCHEMBL18390208 | 0.82 | LGALS8 (0.30) | — | |
| SCHEMBL16729887 | 0.82 | LGALS8 (0.30) | — | |
| SCHEMBL20966340 | 0.81 | LGALS8 (0.41) | — | |
| SCHEMBL21374841 | 0.81 | LGALS8 (0.41) | — | |
| SCHEMBL13706079 | 0.80 | TLR4 (0.31) | — | |
| SCHEMBL26029385 | 0.80 | TLR4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210220386-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | CA1 4834/4885CA2 4841/4885CA9 4775/4885 |
| US-20210220386-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, RBM17, SMN1; SMN2 | CA1 4852/4885CA2 4823/4885CA9 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.